Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults

Metabolism: Clinical and Experimental

Volumn 57, Issue 4, 2008, Pages 494-501

  Aquilante, Christina L ^a   Kosmiski, Lisa A ^b   Knutsen, Shannon D ^a   Zineh, Issam ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN;

ADULT; ARTICLE; BLOOD CELL COUNT; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CHEMOKINE CXCL5; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REGRESSION ANALYSIS; RESISTIN;

EID: 39849084380     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.11.010     Document Type: Article

References (31)

1. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
2. Bokarewa M., Nagaev I., Dahlberg L., Smith U., and Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 174 (2005) 5789-5795
3. Ghanim H., Dhindsa S., Aljada A., Chaudhuri A., Viswanathan P., and Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 91 (2006) 3553-3558
4. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300 (2003) 472-476
5. Savage D.B., Sewter C.P., Klenk E.S., Segal D.G., Vidal-Puig A., Considine R.V., et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50 (2001) 2199-2202
6. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., et al. The potential role of resistin in atherogenesis. Atherosclerosis 182 (2005) 241-248
7. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
8. Harsch I.A., Koebnick C., Wallaschofski H., Schahin S.P., Hahn E.G., Ficker J.H., et al. Resistin levels in patients with obstructive sleep apnoea syndrome-the link to subclinical inflammation?. Med Sci Monit 10 (2004) CR510-CR515
9. Hu W.L., Qiao S.B., Hou Q., and Yuan J.S. Plasma resistin is increased in patients with unstable angina. Chin Med J (Engl) 120 (2007) 871-875
10. Pilz S., Weihrauch G., Seelhorst U., Wellnitz B., Winkelmann B.R., Boehm B.O., et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf) 66 (2007) 380-386
11. Mojiminiyi O.A., and Abdella N.A. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 67 (2007) 215-225
12. Bo S., Gambino R., Pagani A., Guidi S., Gentile L., Cassader M., et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 29 (2005) 1315-1320
13. Kunnari A., Ukkola O., Paivansalo M., and Kesaniemi Y.A. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 91 (2006) 2755-2760
14. Braunersreuther V., Mach F., and Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 97 (2007) 714-721
15. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108 (2003) 736-740
16. Fu Y., Luo L., Luo N., and Garvey W.T. Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutr Metab (Lond) 3 (2006) 28
17. Imaizumi T., Albertine K.H., Jicha D.L., McIntyre T.M., Prescott S.M., and Zimmerman G.A. Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 17 (1997) 181-192
18. Imaizumi T., Kumagai M., Hatakeyama M., Tamo W., Yamashita K., Yoshida H., et al. Effect of 15-deoxy-delta12,14-prostaglandin J2 on IL-1beta-induced expression of epithelial neutrophil-activating protein-78 in human endothelial cells. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 323-327
19. Walz A., Burgener R., Car B., Baggiolini M., Kunkel S.L., and Strieter R.M. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 174 (1991) 1355-1362
20. Walz A., Strieter R.M., and Schnyder S. Neutrophil-activating peptide ENA-78. Adv Exp Med Biol 351 (1993) 129-137
21. Walz A., Schmutz P., Mueller C., and Schnyder-Candrian S. Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease. J Leukoc Biol 62 (1997) 604-611
22. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
23. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88 (2003) 6098-6106
24. Al-Daghri N., Chetty R., McTernan P.G., Al-Rubean K., Al-Attas O., Jones A.F., et al. Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 4 (2005) 10
25. Osawa H., Tabara Y., Kawamoto R., Ohashi J., Ochi M., Onuma H., et al. Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 30 (2007) 1501-1506
26. Hui-Bing H., Migita K., Miyashita T., Maeda Y., Nakamura M., Yatsuhashi H., et al. Relationship between serum resistin concentrations and inflammatory markers in patients with type 2 diabetes mellitus. Metabolism 55 (2006) 1670-1673
27. Ghanim H., Aljada A., Hofmeyer D., Syed T., Mohanty P., and Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110 (2004) 1564-1571
28. Kim C.S., Park H.S., Kawada T., Kim J.H., Lim D., Hubbard N.E., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30 (2006) 1347-1355
29. Martinovic I., Abegunewardene N., Seul M., Vosseler M., Horstick G., Buerke M., et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 69 (2005) 1484-1489
30. de Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
31. Norata G.D., Ongari M., Garlaschelli K., Raselli S., Grigore L., and Catapano A.L. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 156 (2007) 279-284